India: Delhi High Court’s Decision On Teva Pharmaceutical’s Plaint Against Natco

Last Updated: 29 April 2014
Article by Saipriya Balasubramanian

Most Read Contributor in India, September 2016

The Delhi High Court in its recent judgment1 has returned Teva Pharmaceutical's (the Plaintiffs) plea against NATCO (the Defendant) seeking permanent injunction for restraining NATCO from manufacturing Glatiramer Acetate product (Copaxone) for sale in the US. The main reason for the return of plaint as stated in the decision is that the pleadings relating to the product copaxone being sold in Delhi or elsewhere, or the possibility of copaxone being launched in Delhi or elsewhere do not fall into the ambit of the jurisdiction of Delhi High Court. Copaxone (Glatiramer Acetate or Copolymer 1) is used in the treatment of multiple sclerosis.


Teva Pharmaceuticals Industries Ltd ('Teva'), Yeda Research and Development Co.Ltd ('Yeda') and Regent Drugs Ltd ('RDL') filed a suit (CS (OS) No. 1708 of 2007) against NATCO in Delhi High Court restraining the Defendant from infringement of the Indian Patent No.190759 and the rights associated with 'Glatimer'. Further, the Plaintiffs pleaded for restraining NATCO and its agents from exporting the infringing drugs, formulations/bulk drugs outside India. In a reply statement, the counsel for NATCO stated that the process of manufacture of glatiramer acetate which is marketed as 'Glatimer' is entirely different from the process mentioned in the Patent No.190759. Subsequently, NATCO filed a counter claim for revocation of the Indian Patent No.190759, mentioning that the claims covered under the said patent did not meet the criteria for patentability under the Patents Act, 1970.


In an article published in 'Business Line' on 17th January, 2012 it was reported that NATCO collaborated with US based Mylan Pharmaceuticals Inc. ('Mylan') to launch glatiramer acetate in India for the treatment of multiple sclerosis2 . The Plaintiffs further cited the annual report (2010-2011) published by NATCO, and reinstated that NATCO and Mylan signed an agreement relating to the development and marketing of glatiramer acetate in the US which thereby amounts to clear infringement of the Indian Patent.No.190759 and hence sought permanent injunction restraining NATCO from manufacturing Glatiramer Acetate product in India for sale in the US vide CS (OS) No. 3193 of 2012.

Further, Teva filed its second Indian suit, C.S. (O.S) 3193/2012, on grounds that NATCO's manufacture of glatiramer acetate in India for sale in the US and elsewhere infringed its Indian Patent 190759. In its findings, the US Court found that the glatiramer acetate product that Mylan and NATCO sought to sell in the US infringed the claims of US6054430 and US6048898. Therefore, the US Court decided that NATCO's act of manufacturing the glatiramer acetate product for sale in the US and elsewhere amounted to clear infringement of the Indian Patent No.190759 and liable to be restrained by permanent injunction. With regards to this suit, it is further stated by the order of the Hon'ble Delhi High Court that NATCO counterclaimed and sought a declaratory judgment of non-infringement and invalidated the aforementioned US patents.

In response to Teva's second Indian suit, C.S. (O.S) 3193/2012, NATCO filed an application under Order VII Rule 10 CPC vides IA No. 10390 for return of plaint for want of jurisdiction. NATCO further filed IA No. 10389 of 2013 under Order VII Rule 11 CPC seeking rejection of the plaint. NATCO also filed IA No.10638 of 2013 under Sections 10 and 11 of the CPC praying that further proceedings in CS(OS) No.3193 of 2012 should be stayed in view of the pendency of the earlier suit CS (OS) No. 1708 of 2007.


With regards to the application filed by the Plaintiffs under Order VII Rule 10 of the CPC, 1908 i.e IA No.10390 of 2013 questioning the jurisdiction of Court, the Court decided the application.

As per the arguments of the Plaintiffs, the Defendants had sought for regulatory approval for glatiramer acetate and has distribution networks in Delhi, through which the product glatiramer acetate is being sold in Delhi by the Defendants. Also, according to the Plaintiffs, the Defendants used two different processes for the manufacture of Glatiramer acetate, one for sale within India and the other for export to Mylan. This 2012 suit was not relating to the process used by Defendants for making the Glatiramer Acetate product for the Indian market ("GA-first product"). Instead, it was concerned with the process for making the Glatiramer Acetate product that the Defendant is manufacturing in India on behalf of Mylan for sale outside India ("GA-second product"). Therefore the cause of action in suit CS (OS) No.1708 of 2007 is quite different from that of CS (OS) No.3193 of 2012 and the prayers contained therein are clearly distinct.

It is stated by the Plaintiffs that NATCO has marketing approval to sell glatiramer acetate in India and therefore there is a reasonable anticipation and apprehension that the product manufactured by Mylan process will be sold in India without NATCO having to obtain a second market approval from the Indian regulatory agencies.


It has been submitted by NATCO that it does not have any manufacturing facility in New Delhi and neither practices the process nor exports the product from Delhi. NATCO manufactures Copolymer -1 under the mark 'GLATIMER' but not at Delhi. The Defendants observed that nowhere in the Plaint it was alleged that the process being used by the Defendants within the Delhi High Court's jurisdiction. Further, it was pointed out that the product patent on glatiramer acetate, 93/ Del/2003, was rejected by the Indian Patent Office in March 2009 and therefore the Plaintiff has no enforceable rights in respect of the resultant product. It is worthy to note that NATCO had reportedly denied the use of the patented process within the Court's jurisdiction, and had also denied export of the drugs from New Delhi.


The Court noted that CS (OS) No. 3193 of 2012, as stated by the Plaintiffs, is a quia timet action. The Court also observed that "Only an apprehension has been expressed that Natco, having tied up with Mylan, is likely to export the infringing Copolymer-I to US and other countries". The Court further stated that 'the case of the Plaintiffs concerns the infringement of the process involved in the GA-second product, which the Plaintiffs term as the 'Mylan process' and about the possible infringement for the purposes of 'export' of the said product to the US and elsewhere."

The Court clearly stated that since the suit is for a process patent, the pleading as regards to the product being sold in Delhi, or elsewhere or the possibility of it being launched in Delhi or elsewhere cannot justify the jurisdiction of the court." in para 40 of the plaint it is averred that "The US Court decision leads to an incontrovertible conclusion of infringement of rights of Plaintiffs No. 1 and 2 in IN '759 based on the manufacture of glatiramer acetate by Defendant No.2 for export and sale in the United States." . The Court further affirmed that the plaint CS (OS) No. 3193 of 2012 failed to make out a case for the Court to entertain the suit within its jurisdiction and hence directed the plaint to be returned to the Plaintiffs.


It is very noteworthy to consider the pointers mentioned in the Delhi HC order with regards to the structure of pleadings in case of quia timet proceedings. The averments in a plaint alleging infringement or apprehended infringement of a process patent have to be precise. The court referred to the decision in Astrazeneca Canada Inc v. Novopharm Limited in adopting 'Wordsmithing' in pleadings. Further, possibility that the Court is not entertaining pleadings that lacked material facts cannot be ruled out. The Court further held that the facts pleaded must be cogent, precise and material as it is not sufficient that pleadings are indefinite or speak only of intention or amount to mere speculation.




The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.